Fig. 1From: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatmentSynthesis of 212Pb-TCMC-YS5 and in vitro cell binding study. A Reaction scheme for 212Pb-TCMC-YS5 synthesis. B Size-exclusion HPLC analysis of 212Pb-TCMC-YS5. C In vitro cell binding assay of 212Pb-TCMC-YS5 on PC3 cells. Triplicates. Apparent binding affinity (KD) was calculated by curve fittingBack to article page